CGTLive’s Weekly Rewind – September 16, 2022


Review top news and interview highlights from the week ending September 16, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. IL13Rα2 Universal CAR T Therapy Shows Antitumor Activity in Recurrent Glioma

MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.

2. Phase 1 Clinical Trial Will Assess CAR-T With Genetic and Epigenetic Reprogramming for Solid Tumors

Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.

3. Ide-Cel to Be Evaluated in Newly Diagnosed Multiple Myeloma

The announcement comes after positive top-line results in the ongoing KarMMa-3 study.

4. ICER Throws Support Behind Clinical, Cost Value of Hemophilia Gene Therapies in Draft Report

A substantial benefit noted for EtranaDez and val-rox is that they are delivered as a single-dose.

5. Weijia Fang, MD, and Tianhang Luo, MD, on EpCAM-Targeted CAR-T Therapy in Advanced Colorectal and Gastric Cancer

Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.

Related Videos
Sharon Hesterlee, PhD
Thomas Crawford, MD, on Helping Patients With SMA Left Behind by Gene Therapy
J. Andrew Livingston, MD
Pat Furlong, BSN, RN, on Future Areas of Research in DMD
Michael Kelly, PhD, on Continuing Progress in Muscular Dystrophy in 2024
Thomas McCauley, PhD, on Continuing Evaluations on OTX-2002 for MYC-Expressing Cancers
© 2023 MJH Life Sciences

All rights reserved.